Rodos Biotarget, a Hannover, Germany-based life science company, raised €800k in funding.
Medical entrepreneur and business angel Otto H. Gies made the investment in a round further accompanied by High-Tech Gründerfonds and Hannover Investimpuls Fonds.
The company intends to use the funds for further corporate development.
Led by CEO Dr. Marcus Furch, Rodos has developed a platform technology called TargoSphere® for nanocarrier-enabled targeted and efficient drug delivery. This technology is suitable for prophylactic and therapeutic applications in various disease areas of high medical need. These include cancers, chronic infections, autoimmune diseases, and neurological disorders.
For commercializing its patented technology platform, the company primarily relies on collaborations with major pharmaceutical companies. In addition, it promotes in-house therapy developments including TargoBioticsTM for the treatment of intracellular bacterial infections, TargoVirTM for the treatment of chronic viral diseases, and further nanomedicines for the treatment of type 2 diabetes and liver diseases such as acute liver failure, liver fibrosis, urea cycle deficiencies and liver cancer.
Rodos raised a first round with Seedmatch in 2016 and is running a campaign with aescuvest right now.